The UK is poised to become the first country in the world to launch a new payment model for antibiotics that could reverse decades of decline in the category.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh